



**World Health
Organization**

**Options for Live Attenuated Influenza Vaccines (LAIV)
In the Control of Epidemic and Pandemic Influenza
12-13 June 2007**

Meeting venue: WHO/HQ, Salle A

AGENDA

Chairperson: Dr Arnold Monto

Rapporteur: Mrs Allison Hunter

Tuesday 12 June

9:00

Welcome and purpose of meeting

Dr M.T. Aguado

Introduction and presentation of participants

Dr D. Wood

General information

Dr L. Palkonyay

Meeting background

9:30 - 9:50

Updating the LAIV guidance document: a WHO objective

Dr D. Wood/C. Alfonso

9:50 - 10:10

Live attenuated influenza vaccines and the
global challenge of pandemic influenza: a call for review

Dr L. Palkonyay

10:10 - 10:30

The intellectual property landscape: backbone strains and
reverse genetics

Dr M. Friede

10:30 - 11:00

Tea/Coffee

Historical perspectives

11:00 - 11:30

Fifty years historical experience with live
attenuated influenza vaccines in Russia

Dr L. Rudenko

11:30 - 12:00

From strain development to licensure:
the live attenuated influenza vaccine in the USA

Dr J. Young

12:00 - 13:30 *Lunch*

**Public health perspectives:
in epidemic influenza**

13:30 - 14:00

Efficacy and effectiveness in children

Dr T. Vesikari

14:00 - 14:30

Efficacy and effectiveness in adults

Dr K. Edwards

14:30 - 15:00

School settings:
new target groups for influenza vaccination

Dr J. King

15:00 - 15:30

Herd immunity through targeted live
influenza vaccination: myth or reality?

Dr P. A Piedra

15:30 - 16:00 *Tea/Coffee*

**Live attenuated and inactivated influenza vaccines:
how do they compare?**

16:00 - 16:30

Historical face-to-face comparison experience
in Russia

Dr A. Monto

16:30 - 17:00

Comparative studies in infants and young children:
safety and efficacy

Dr K. Edwards

17:00 - 17:30

Face-to-face comparison in adults:
safety and efficacy

Dr A. Monto

Wednesday 13 June**9:00****Specific challenges for the introduction of seasonal LAIV vaccines**

9:00 - 9:30

Safety in special populations

Dr N. Baylor

9:30 - 10:00

WHO collaborative centers: seed virus, reagent development and distribution

Dr A. Klimov

10:00 - 10:30

Regulatory issues: thermal stability, SPF eggs, perceived environmental risks through shedding, biosafety level requirements for safe production, assessment of attenuation.

Dr Z. Ye

10:30 - 11:00*Tea/Coffee***Future production of LAIV in tissue culture: is it realistic?**

11:00 - 11:30

Development plans in North-America

Dr G. Kemble

11:30 - 12:00

Development plans in Europe

Dr T. Voeten

12:00 - 12:30

Replication deficient Del NS1 influenza vaccine produced in Vero cells

Dr A. Egorov

12:30 - 13:30*Lunch***Pandemic challenges**

13:30 - 14:00

Veterinary biosafety aspects of manipulating influenza viruses derived from strains of high avian pathogenicity

Dr G. Dauphin

14:00 - 14:30

Preclinical evaluation of LAIV prototype pandemic vaccines derived from highly pathogenic strains

Dr K. Subbarao

14:30 - 15:00

Clinical trial challenges for pre-approval of an H5 type LAIV prototype pandemic vaccine: endpoint and biosafety

Dr J. Weir

15:00 - 15:30

Inclusion of LAIV into the WHO guidelines for the production and quality control of human pandemic influenza vaccines: is it time now for such an extension of the document?

Dr J. Wood

15:30 – 15:45 *Tea/Coffee*

15:45 - 16:15

LAIV Administration: Capacity and Challenge to Develop and Test a Device for Pandemic Utilization

Dr B. Machielse

Meeting conclusions

16:15 – 17:15

Discussion on options for LAIV in seasonal and pandemic influenza: future research directions

All participants

17:15 - 17:30

Meeting summary: research priorities for LAIV

Chair and Rapporteur